Literature DB >> 9731940

Flunarizine in migraine prophylaxis: predictive factors for a positive response.

C Lucetti1, A Nuti, N Pavese, G Gambaccini, G Rossi, U Bonuccelli.   

Abstract

The efficacy of flunarizine in migraine prophylaxis is confirmed in both open and controlled trials. However, it is unknown what factors may influence a good response to prophylaxis with flunarizine. The aim of this study was to determine the possible predictive factors for therapeutic responsiveness to 3 months' treatment with flunarizine. One-hundred headache patients treated with flunarizine were evaluated. We considered "responders" those patients who recorded a reduction in migraine frequency of 75% after treatment. Statistical analysis revealed four factors which might influence therapeutic responsiveness in our patients. Positive factors were a family history (p<0.01) and high intensity of pain (p<0.01); negative factors were frequent attacks (p<0.01) and a history of analgesic abuse (p<0.001). Patients with no previous history of analgesic abuse, low frequency of attacks at baseline, higher levels of migraine pain, and positive family history constitute the prototype of flunarizine long-term treatment responders.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9731940     DOI: 10.1046/j.1468-2982.1998.1806349.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  6 in total

Review 1.  Practical considerations for the treatment of elderly patients with migraine.

Authors:  Paola Sarchielli; Maria Luisa Mancini; Paolo Calabresi
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

2.  Hypothalamic involvement in chronic migraine.

Authors:  M F Peres; M Sanchez del Rio; M L Seabra; S Tufik; J Abucham; J Cipolla-Neto; S D Silberstein; E Zukerman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-12       Impact factor: 10.154

3.  Effects of flunarizine on spontaneous synaptic currents in rat neocortex.

Authors:  P T Golumbek; J M Rho; W J Spain; J F M van Brederode
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-01       Impact factor: 3.000

4.  Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial.

Authors:  Anjali Lepcha; Sophia Amalanathan; Ann Mary Augustine; Amit Kumar Tyagi; Achamma Balraj
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-29       Impact factor: 2.503

5.  Factors Associated with Favorable Outcome of Topiramate Migraine Prophylaxis in Pediatric Patients.

Authors:  Il Han Yoo; WooJoong Kim; Hunmin Kim; Byung Chan Lim; Hee Hwang; Jong Hee Chae; Jieun Choi; Ki Joong Kim
Journal:  J Clin Neurol       Date:  2017-07       Impact factor: 3.077

6.  Patient outcome in migraine prophylaxis: the role of psychopharmacological agents.

Authors:  Maurizio Pompili; Gianluca Serafini; Marco Innamorati; Giulia Serra; Giovanni Dominici; Juliana Fortes-Lindau; Monica Pastina; Ludovica Telesforo; David Lester; Paolo Girardi; Roberto Tatarelli; Paolo Martelletti
Journal:  Patient Relat Outcome Meas       Date:  2010-09-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.